Parkinson’s Disease Therapeutics Market By Drug Class (Dopamine Agonists, Levodopa/ Caxrbidopa, Anticholinergic Drugs, Monoamine Oxidase B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT) Inhibitors and Adenosine A2 Receptor Antagonist) - Growth, Future Prospects and Competitive Analysis, 2018 – 2026
Parkinson’s disease (PD), is progressive nervous system disorders, characterized by tremor, rigidity, bradykinesia, and postural instability. It is estimated that, the global Parkinson’s disease therapeutics market will show significant market growth over the forecast period from 2018 to 2026. Some key factors that drive PD therapeutics market growth are large unmet needs, projected launch of prominent pipeline drugs (APL-130277, Accordion Pill, P2B-001, ND0612H etc.), increase in research and development activities for development of novel PD therapeutics and growing incidence of PD.
The report titled “Parkinson’s Disease Therapeutics Market – Growth, Future Prospects and Competitive Analysis, 2018 – 2026” covers detailed analysis of PD therapeutics market for period from 2016 to 2026. For the purpose of comprehensive study of PD therapeutics, this market is segmented on the basis of major drug classes such as dopamine agonists, levodopa/ caxrbidopa, anticholinergic drugs, monoamine oxidase B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors and adenosine A2 receptor antagonist.
To provide detail information regarding geographical market trends and future market prospect geographically, the global PD therapeutics market is classified on the basis of main regional markets such as North America, Europe, Latin America, Asia Pacific and Middle East and Africa. For country level analysis, PD therapeutics market is classified into United States, Canada, Germany, United Kingdom, rest of Europe, Brazil, Mexico, Rest of Latin America, Japan, China, rest of Asia Pacific, GCC and rest of Middle East and Africa.
This report includes information regarding the current market trends and future market scenario for PD therapeutics; while presenting statistical data along with qualitative information. For better understanding about the ongoing trends of PD therapeutics market and future market projections, exhaustive information about the market opportunities, drivers and challenges in global PD therapeutics market are included in report. For further understanding about the R&D study and their impact on future market scenario, pipeline analysis is included in this report with detailed analysis and market estimation provided for phase 3 drugs. To provide insight on the important players involved in global PD therapeutics market, competitive landscape, and company profiles sections are included in this report.
Based on drug class, the global Parkinson’s disease therapeutics market is segmented as follows:
- Dopamine Agonists
- Levodopa/ carbidopa
- Anticholinergic Drugs
- Monoamine Oxidase B (MAO-B) Inhibitors
- Catechol-O-Methyltransferase (COMT) Inhibitors
- Adenosine A2 Receptor Antagonist
Parkinson’s disease (PD) is disorder of the nervous system that affects movement; it progresses gradually and sometimes starts with a noticeable tremor. Drugs that increase the dopamine level and those that control non-motor symptoms are used for management of PD. Currently, dopamine receptor agonists such as pramipexole, ropinirole, Bromocriptine, rotigotine, apomorphine etc. preferably used in market; as alone or in combination with levodopa/ carbidopa. Dopamine agonists are not as potent as levodopa and cause less dyskinesias. Levodopa couples with decarboxylase inhibitor drug - carbidopa remains the standard treatment for Parkinson’s disease, which shows fewer advarese effect in short term use. Newly approved drugs such as nouriast and preregistration phase drugs such as CVT-301 expected to drive significant market growth during forecast period. Furthermore, late stage pipeline drugs such as APL-130277, Accordion Pill, P2B-001, ND0612H etc. would facilitate market growth in the coming years.
For the purpose of this study, the global Parkinson’s disease therapeutics market is categorized into:
- North America
- United States
- Canada
- Europe
- U.K.
- Germany
- Rest of Europe
- Asia Pacific
- China
- Japan
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- Rest of Middle East and Africa
According to the World Health Organization (WHO), PD is a universal disorder, with a crude incidence rate of 4.5 to 19 per 100,000 population per year. According to the Parkinson's Disease Foundation, PD affects about 1 million people in the United States and more than 4 million people worldwide. About 60,000 people are diagnosed each year in the United States. Among the considered geographical markets, North America is dominating the PD therapeutics market owing to some key factors such as higher target population pool, developed healthcare infrastructure, early diagnosis of disease, extensive research and development for novel drugs, and wide accessibility for novel therapeutics. Asia Pacific is set to capture significant position in coming years on account of improving healthcare infrastructure, rising treatment awareness among the general population, growing incidence of PD. Asia Pacific is base to enormous population pool that is continually growing, thus there is a corresponding increase in incidence of PD that would further lead to increase demand of PD therapeutics.
Chapter 1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Phase III-Expert Panel Review
1.3.4. Assumptions
Chapter 2. Executive Summary
2.1. Global Parkinson’s Disease Therapeutics Market Portraiture
2.1.1. Global Parkinson’s Disease Therapeutics Market, by Drug Class, 2017 (US$ Mn)
2.1.2. Global Parkinson’s Disease Therapeutics Market, by Geography, 2017 (Value %)
Chapter 3. Parkinson’s Disease Therapeutics: Market Dynamics and Outlook
3.1. Market Definition and Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Landscape
3.6.1. Competitive Landscape: Global Parkinson’s Disease Therapeutics Market, by Key Players, 2017
Chapter 4. Global Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Dopamine Agonists
4.3. Levodopa/ Carbidopa
4.4. Anticholinergic Drugs
4.5. Monoamine Oxidase B (MAO-B) Inhibitors
4.6. Catechol-O-Methyltransferase (COMT) Inhibitors
4.7. Adenosine A2 Receptor Antagonist
4.8. Pipeline Candidates: Overview
4.8.1. Phase III (Market estimations by 2026)
4.8.1.1. APL-130277 (Cynapsus Therapeutics-Sunovion)
4.8.1.2. Accordion Pill Carbidopa/Levodopa (Intec Pharma)
4.8.1.3. P2B-001 (Pharma Two B)
4.8.1.4. ND0612H (Neuroderm)
4.8.2. Phase II & I (Tabular Information)
Chapter 5. Global Parkinson’s Disease Therapeutics Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. North America Parkinson’s Disease Therapeutics Market Analysis, 2016 – 2026 (US$ Mn)
5.2.1. North America Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.2.2. North America Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Parkinson’s Disease Therapeutics Market Analysis, 2016 – 2026 (US$ Mn)
5.3.1. Europe Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.3.2. Europe Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Parkinson’s Disease Therapeutics Market Analysis , 2016 – 2026 (US$ Mn)
5.4.1. Asia Pacific Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of APAC
5.5. Latin America Parkinson’s Disease Therapeutics Market Analysis , 2016 – 2026 (US$ Mn)
5.5.1. Latin America Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.5.2. Latin America Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa (MEA) Parkinson’s Disease Therapeutics Market Analysis, 2016 – 2026 (US$ Mn)
5.6.1. MEA Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.6.2. MEA Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA
Chapter 6. Company Profiles
6.1. Abbvie, Inc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Biogen, Inc.
6.3. Boehringer Ingelheim GmbH
6.4. F. Hoffman-La Roche
6.5. GlaxoSmithKline Plc.
6.6. H. Lundbeck A/S
6.7. Impax Labs, Inc.
6.8. Newron Pharmaceuticals SpA
6.9. Novartis AG
6.10. Orion Corporation
6.11. Teva Pharmaceutical Industries Ltd.
6.12. UCB S.A.
Table 1 Global Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 2 North America Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 3 North America Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 4 Europe Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 5 Europe Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 6 Asia Pacific Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 7 Asia Pacific Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 8 Latin America Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 9 Latin America Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 10 Middle East and Africa Parkinson’s Disease Therapeutics Market, by Drug Class, 2016 – 2026 (US$ Mn)
Table 11 Middle East and Africa Parkinson’s Disease Therapeutics Market, by Country, 2016 – 2026 (US$ Mn)
Table 12 Abbvie,Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 13 Biogen, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 14 Boehringer Ingelheim GmbH: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 15 F. Hoffman-La Roche: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 16 GlaxoSmithKline Plc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 17 H. Lundbeck A/S: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 18 Impax Labs, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 19 Newron Pharmaceuticals SpA: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 20 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 21 Orion Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 22 Teva Pharmaceutical Industries Ltd. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 23 UCB S.A. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
FIG. 1 Parkinson’s Disease Therapeutics: Market Segmentation
FIG. 2 Global Parkinson’s Disease Therapeutics Market, by Drug Class, 2017 (US$ Mn)
FIG. 3 Global Parkinson’s Disease Therapeutics Market, by Geography, 2017 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2017
FIG. 5 Market Competition Landscape, by Key Players, 2017
FIG. 6 Global Dopamine Agonists Market, 2016 – 2026 (US$ Mn)
FIG. 7 Global Levodopa/ Carbidopa Market, 2016 – 2026 (US$ Mn)
FIG. 8 Global Anticholinergic Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 9 Global Monoamine Oxidase B (MAO-B) Inhibitors Market, 2016 – 2026 (US$ Mn)
FIG. 10 Global Catechol-O-Methyltransferase (COMT) Inhibitors Market, 2016 – 2026 (US$ Mn)
FIG. 11 Global Adenosine A2 Receptor Antagonist Market, 2016 – 2026 (US$ Mn)
FIG. 12 U.S. Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 13 Canada Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 14 U.K. Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 15 Germany Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 16 Rest of Europe Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 17 Japan Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 18 China Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 19 Rest of Asia Pacific Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 20 Brazil Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 21 Mexico Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 22 Rest of Latin America Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 23 GCC Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
FIG. 24 Rest of Middle East and Africa Parkinson’s Disease Therapeutics Market, 2016 – 2026 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)